



ASX AND MEDIA RELEASE

Peplin appoints Chief Medical Officer

Brisbane, Australia and Emeryville, CA, 3 April 2007: Peplin Limited (ASX:PEP) today announced the appointment of Arthur P. Bertolino, MD, PhD as Chief Medical Officer and Vice President, Medical Affairs. Dr Bertolino was previously Clinical Group Head of Dermatology at Pfizer, Inc. (NYSE:PFE) in Ann Arbor, Michigan.

In his most recent role, Dr Bertolino established the clinical arm of dermatology at Pfizer and was instrumental in overseeing the progression of numerous new molecular entities through clinical development. He is a Board-certified dermatologist and has had an extensive scientific and clinical career in dermatology including senior positions in large pharmaceutical and biotechnology companies, academia and private clinical practice.

Dr Bertolino will be based in Peplin's San Francisco Bay Area office and report to Peplin's CEO. He will be responsible for Peplin's later stage clinical development activities and for building a complete medical affairs capability.

Dr Bertolino earned both an MD and PhD from Johns Hopkins University School of Medicine and a Bachelor of Science in Chemistry and Biochemistry from SUNY at Stony Brook. He was formerly the Chief of Dermatology at The Ohio State University and currently maintains an adjunct faculty position at NYU School of Medicine.

Peplin's CEO Michael Aldridge said today that this appointment was a major strengthening of the dermatology focused clinical and product development capabilities of the company and consistent with its strategy of building its operations in the large and strategically important North American market.

"Dr Bertolino has a very strong track record in the development of novel dermatology pharmaceutical products at both pharmaceutical and biotechnology companies", said Mr Aldridge.

"This is enhanced by his academic and private practice experience. We believe we have secured the right mix of skills to move our later stage programs forward most efficiently. We are very pleased to have him join our team at this critical juncture in the growth and development of Peplin.

“This appointment together with our previously announced appointments of Cheri Jones as Vice President, Regulatory Affairs and Philip Moody as Chief Financial Officer and Vice President, Finance and Operations are important steps in expanding both our executive management team and our US operations.

“We also want to recognize Gary Patou’s critical role as interim CMO for the last year. He was responsible for shaping and implementing our phase IIb program and has transitioned back to MPM Capital as planned.”

Further information:

Michael Aldridge
Chief Executive Officer
Tel: +1-510 653 9700
michael.aldridge@peplin.com

Media:

Tim Mullen
Hill & Knowlton
Tel: 02-9286 1272 / 0408 321 312
tmullen@hillandknowlton.com.au

US investors:

Gitanjali Jain
The Trout Group
Tel: +1-646-378-2949

ABOUT PEPLIN

Peplin is focused on the development and commercialisation of medical dermatology products and in particular a novel topical product to treat skin cancer and pre-cancerous lesions. Peplin’s lead compound is PEP005, the first in a new class of investigational agents. Peplin’s lead product has shown significant promise in phase II clinical trials for the treatment of actinic (solar) keratosis (AK), a very common pre-cancerous lesion and basal cell carcinoma (BCC), the most common form of skin cancer. Peplin believes the unique benefits of its lead product may include a very short course of therapy and a transient and favourable side effect profile. Peplin’s product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin’s earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intracavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 and related molecules.